Mavacamten and left ventricular dysfunction in hypertrophic cardiomyopathy with left bundle branch block - PubMed
3 hours ago
- #Mavacamten
- #Hypertrophic Cardiomyopathy
- #Left Bundle Branch Block
- Mavacamten is a cardiac myosin inhibitor used in obstructive hypertrophic cardiomyopathy (oHCM).
- Study explores mavacamten's effect on left ventricular function and dyssynchrony in oHCM patients with left bundle branch block (LBBB).
- LBBB presence is associated with increased risk of LV systolic dysfunction after mavacamten treatment.
- LV ejection fraction significantly decreased and mechanical dyssynchrony increased in LBBB patients post-treatment.
- Atrial fibrillation, baseline LVEF, and LBBB status are independent predictors of LV dysfunction.